Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sotalol: An important new antiarrhythmic.

J L Anderson1, E N Prystowsky

  • 1University of Utah and St. Vincent'sHospital, Northside Cardiology, Salt Lake City, USA.

American Heart Journal
|February 27, 1999
PubMed
Summary

Sotalol, a unique antiarrhythmic drug, effectively treats ventricular and atrial arrhythmias with a favorable safety profile. Its dual action offers superior efficacy and tolerance compared to other treatments, including class I agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator.

Reviews in cardiovascular medicine·2002
Same author

Hyperventilation facilitates induction of supraventricular tachycardia: a novel method and the possible mechanism.

Journal of cardiovascular electrophysiology·2002
Same author

When technology exceeds knowledge, is success a reasonable expectation?

Journal of cardiovascular electrophysiology·2002
Same author

Report of the NASPE policy conference on arrhythmias and the athlete.

Journal of cardiovascular electrophysiology·2001
Same author

ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Circulation·2001
Same author

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

European heart journal·2001

Area of Science:

  • Clinical Pharmacology
  • Cardiac Electrophysiology
  • Cardiovascular Medicine

Background:

  • Sotalol is an oral antiarrhythmic drug with a unique pharmacologic profile.
  • Its efficacy stems from nonselective beta-blocking and Class III antiarrhythmic activity.
  • This dual action prolongs action potential duration and refractory period, affecting the QT interval.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and safety of sotalol for treating cardiac arrhythmias.
  • To compare sotalol's effectiveness against Class I antiarrhythmic drugs and implantable defibrillators.
  • To assess sotalol's role in managing both ventricular and atrial arrhythmias.

Main Methods:

  • Review of clinical trials, including the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial.
  • Comparison with Class I antiarrhythmic drugs and implantable defibrillators as studied in the National Institutes of Health Antiarrhythmics versus Implantable Defibrillator (AVID) study.
  • Analysis of sotalol's pharmacokinetic properties, including metabolism and excretion.

Main Results:

  • Sotalol demonstrated superior efficacy in preventing recurrent ventricular tachycardia and fibrillation.
  • The ESVEM trial showed increased in-hospital efficacy prediction, reduced long-term recurrence, and lower mortality compared to Class I agents.
  • Sotalol is effective for atrial arrhythmias, comparable to propafenone and quinidine, with better tolerance than quinidine.

Conclusions:

  • Sotalol is a preferred antiarrhythmic agent, particularly for use with implantable defibrillators, due to its efficacy and favorable safety profile.
  • Its major side effects, related to beta-blockade and torsades de pointes, are manageable with appropriate precautions.
  • Sotalol's lack of pharmacokinetic interactions and renal excretion simplify its use, with dosage adjustments necessary in renal failure.

Related Experiment Videos